Current stock page

Catalysts

RYTM Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

RYTMRhythm Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$115.02+$5.16 (+4.70%)

Latest quote

  • Momentum
    72
  • Value
    52
  • Quality
    60
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 25, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 62/100

Momentum 72/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 16.45%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 72/100AIQ Edge 7/10 Above Peers
Beat rate
50%
4 of 8 reported periods
Average surprise
-1.8%
Across covered historical reports
Latest result
+14.0%
Nov 3, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 3, 2026—-$0.71-$0.61+14.0%$85.56M$92.13M
Aug 4, 2026—-$0.81-$0.73+9.6%$67.66M$71.26M
May 5, 2026—-$0.86-$0.83+3.5%$55.78M$60.11M
Feb 26, 2026—-$0.79-$0.73+7.6%$56.21M$57.25M
Nov 4, 2025—-$0.72-$0.82-13.9%$55.98M$51.3M
Aug 5, 2025—-$0.66-$0.75-13.6%$51.33M$48.5M
May 7, 2025—-$0.69-$0.81-17.4%$43.28M$32.7M
Feb 26, 2025—-$0.69-$0.72-4.3%$38.48M$41.83M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
17
Buy
2
Hold
12-month analyst target
$136.33
+18.53% versus current price
Based on 19 analyst observations. Targets are estimates, not predictions.
Low target
$120.00
+4.33% vs latest price
Average target
$136.33
+18.53% vs latest price
High target
$159.00
+38.24% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 25, 2027

Next known earnings or reporting date.

EPS estimate-$2.59

Current analyst expectation for the upcoming report.

Revenue estimate$109.65M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score72

Where event reaction would show up first.

AIQ score62/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
19
Average target
$136.33
Target upside
18.53%
Target range
$120.00 - $159.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
0
Negative
1
seekingalpha.com · Nov 10, 2026

Rhythm Pharmaceuticals Stock: Bull Case Intact, But The Market Is Pricing In A Lot (RYTM)

Rhythm Pharmaceuticals is a Buy on 79.5% YoY IMCIVREE sales growth, though 27.4x trailing sales and costs raise execution risk. Read more on RYTM stock here.

zacks.com · Nov 3, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +10.29% and +9.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

gurufocus.com · Oct 16, 2026

RYTM Initiates Coverage On by William Blair -- Rating Outperform

On October 16, 2026, Rhythm Pharmaceuticals (RYTM) received an 'Outperform' rating from William Blair, marking a significant endorsement for the company. Howeve

insidermonkey.com · Sep 11, 2026

Billionaire Stanley Druckenmiller’s 2 New Healthcare Stock Picks

Stanley Druckenmiller's Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc.

Open full news and sentiment

RYTM Catalysts FAQ

What are the next catalysts for RYTM stock?

RYTM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move RYTM stock?

Upcoming events that could move RYTM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could RYTM's next earnings report affect the stock?

RYTM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive RYTM stock higher?

RYTM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt RYTM stock?

RYTM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.